RWD38 Early Treatment Modification for Type 2 Diabetes in a US Real-World Population: Impact on Glycemic Control, Diabetic Complications, and Healthcare Utilization

C Uzoigwe,Y Liang,J Noone,Sm Whitmire,M Guevarra,Y Paprocki

doi:10.1016/j.jval.2022.04.1562

RWD38 Early Treatment Modification for Type 2 Diabetes in a US Real-World Population: Impact on Glycemic Control, Diabetic Complications, and Healthcare Utilization

C Uzoigwe, Y Liang + Show 4 more

Open Access

https://doi.org/10.1016/j.jval.2022.04.1562

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jun 25, 2022
License type: publisher-specific-oa

Affiliation: Novo Nordisk (United States)

#Healthcare Utilization In Patients #US Real-World + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

To evaluate the prevalence of early treatment modification and estimate its impact on glycemic control, diabetic complications, and healthcare utilization in patients with type 2 diabetes (T2D) and HbA1c ≥9%.

Full Text